101588-11-8

Basic information

• Product Name: C₁₇H₂₀N₂O₄
• Synonyms: C₁₇H₂₀N₂O₄
• CAS NO: 101588-11-8
• Molecular Weight: 316.357
• Mol File: 101588-11-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: C₁₇H₂₀N₂O₄(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₇H₂₀N₂O₄(101588-11-8)
• EPA Substance Registry System: C₁₇H₂₀N₂O₄(101588-11-8)

Safety Data

• Hazardous Substances Data: 101588-11-8(Hazardous Substances Data)

Upstream product

• 156-38-7 4-hydroxyphenylacetate 
• 861065-72-7 [4-(4-methoxy-phenoxy)-3,5-dinitro-phenyl]-acetic acid ethyl ester 
• 83799-60-4 (4-hydroxy-3,5-dinitro-phenyl)-acetic acid ethyl ester 
• 150-76-5 4-methoxy-phenol 

Downstream Products

• 67-30-1 tetrac 
• 1155-40-4 2-(4-(4-hydroxyphenoxy)-3,5-diiodophenyl)acetic acid 
• 1300559-71-0 methyl {4-[4-(2-chloroethoxy)-3,5-diiodophenoxy]-3,5-diiodophenyl}-acetate 
• 1300559-73-2 Lithium [4-(4-{2-[(diaminomethylene)amino]ethoxy}-3,5-diiodophenoxy)-3,5-diiodophenyl]acetate 
• 1300559-75-4 (4-{4-[2-(carbamoylamino)ethoxy]-3,5-diiodophenoxy}-3,5-diiodophenyl)acetic acid 
• 1300559-77-6 {4-[4-(3-aminopropoxy)-3,5-diiodophenoxy]-3,5-diiodophenyl}acetic acid 
• 85828-82-6 [3,5-diiodo-4-(4-methoxy-phenoxy)-phenyl]-acetic acid ethyl ester 
• 1300857-63-9 C₁₈H₁₇I₄NO₄ 
• 1300559-73-2 lithium [4-(4-{2-[(diaminomethylene)amino]-ethoxy}-3,5-diiodophenoxy)-3,5-diiodophenyl]acetate 
• 92436-93-6 2-(3,5-diiodo-4-(4-methoxyphenoxy)phenyl)acetic acid 

Relevant articles and documents

Synthesis of new analogs of tetraiodothyroacetic acid (tetrac) as novel angiogenesis inhibitors for treatment of cancer

In the angiogenesis process, integrins, which are members of a family of cell surface transmembrane receptors, play a critical role particularly in blood vessel formation and the local release of vascular growth factors. Thyroid hormones such as L-thyroxine (T4) and 3,5,3′-triiodo-L-thyronine (T3) promote angiogenesis and tumor cell proliferation via integrin αvβ3 receptor. At or near an arginine-glycine-aspartate (RGD) recognition site on the binding pocket of integrin αvβ3, tetraiodothyroacetic acid (tetrac, a deaminated derivative of T4) is a thyrointegrin receptor antagonist and blocks the actions of T3 and T4 as well as different growth factors-mediated angiogenesis. In this study, we synthesized novel tetrac analogs by modifying the phenolic moiety of tetrac and tested them for their anti-angiogenesis activity using a Matrigel plug model for angiogenesis in mice. Pharmacological activity results showed that tetrac can accommodate numerous modifications and maintain its anti-angiogenesis activity.

COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS

A dual thyrointegrin antagonist and a method for treating an angiogenesis-mediated disorder and/or a hyperthyroidism disorders by introducing the dual thyrointegrin antagonist into animals (e.g., mammals, human beings). The dual thyrointegrin antagonist includes a chemical structure having a thyroid hormone antagonist and alphavbeta3 integrin antagonist in the same molecule